Shares of biotechnology company Inovio Pharmaceuticals (NASDAQ: INO) have recently been on a sharp decline. Over the course of five consecutive sessions, the company’s stock plummeted by more than 16%, dropping to sh.42. This drop contributed significantly to NATDAQ’s overall decrease of 1.12%. As of now, Inovio Pharmaceuticals’ shares are trading at prices 84.93% lower than their 52-week high of .82. This marks the company’s worst performance in its history.
Inovio’s Services
Despite these setbacks in the stock market, Inovio Pharmaceuticals continues to stand out in the biotechnology industry. The company is highly dedicated to discovering, developing, and commercializing DNA medicines. The primary intent behind these medicines is to treat and prevent conditions such as human papillomavirus (HPV), cancer, and other infectious diseases.
Financial Difficulty
Although Inovio Pharmaceuticals has made significant contributions to medical research, it continues to struggle financially. While the company’s earnings per share (EPS) over the trailing twelve months was somewhat satisfactory at 1.01, its efforts in R&D did not lead to an increase in return on equity (ROE). During the same period, the company’s ROE hit a concerning low of negative 87.1%.
Furthermore, Inovio’s quarterly revenue has been less than ideal. Over the last twelve months, its growth decreased by a massive 42.3%, leaving the total revenue for the trailing twelve months at a mere $10M.
Inovio’s Stock Performance
When observing Inovio Pharmaceuticals’ 52-week high and low stock values, it is evident that the company is in a downward spiral. Currently, its stock is trading below its 52-week high of sh.644, although it is slightly above its 52-week low of sh.385. This decline is further highlighted by the company’s stock falling significantly below both its 50-day moving average of sh.54 and its 200-day moving average of .244.
The Future of Inovio
All these factors underline the pressing need for Inovio Pharmaceuticals to take strategic measures to boost profitability and restore the trust of its investors. The company’s current situation also underlines the importance of financial literacy. Understanding how a company’s performance within an industry influences stock market profitability is an invaluable asset for any investor.
More news about Inovio Pharmaceuticals (INO).
